Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.12.2 (
MEK
)
18,161
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Activity of FOXO (forkhead box O) transcription factors is inhibited by growth factor-PI3K (phosphoinositide 3-kinase)-PKB (protein kinase B)/Akt signalling to control a variety of cellular processes including cell cycle progression. Through comparative analysis of a number of microarray datasets we identified a set of genes commonly regulated by FOXO proteins and PI3K-PKB/Akt, which includes
CTDSP2
(C-terminal domain small phosphatase 2). We validated
CTDSP2
as a genuine FOXO target gene and show that ectopic
CTDSP2
can induce cell cycle arrest. We analysed transcriptional regulation after
CTDSP2
expression and identified extensive regulation of genes involved in cell cycle progression, which depends on the phosphatase activity of
CTDSP2
. The most notably regulated gene is the CDK (cyclin-dependent kinase) inhibitor p21(Cip1/Waf1) and in the present study we show that p21(Cip1/Waf1) is partially responsible for the cell cycle arrest through decreasing cyclin-CDK activity. Our data suggest that
CTDSP2
induces p21(Cip1/Waf1) through increasing the activity of Ras. As has been described previously, Ras induces p21(Cip1/Waf1) through p53-dependent and p53-independent pathways and indeed both p53 and
MEK
inhibition can mitigate the
CTDSP2
-induced p21(Cip1/Waf1) mRNA up-regulation. In support of Ras activation by
CTDSP2
, depletion of endogenous
CTDSP2
results in reduced Ras activity and thus
CTDSP2
seems to be part of a larger set of genes regulated by FOXO proteins, which increase growth factor signalling upon FOXO activation.
...
PMID:FOXO target gene CTDSP2 regulates cell cycle progression through Ras and p21(Cip1/Waf1). 2599 Mar 25